Role of Lenalidomide in CLL
In chronic lymphocytic leukemia (CLL), tumour cells do not form stable cognate interactions with CD4+ and CD8+ T cells for a number of reasons including an impaired clustering and activation of lymphocyte function-associated antigen-1 (LFA-1).
As well, CLL cells induce profound modifications of T-cell transcriptomes that further endanger the formation of effective immune synapses resulting in defective antitumour responses. Lenalidomide, an immunomodulatory drug, causes the downregulation of CLL ligands, restores the stabilization of effective immune synapses and rescues the function of LFA-1. To read more, click here.